Overseas Assessment Services & Pricing
Zero training, zero learning curve — delivered as finished work, with all analysis completed by Qiyang. For a small cost, turn "going overseas" from an idea into an executable first step.
Built for going-overseas decisions
Small and mid-size pharma face the same hurdles when going overseas: not knowing which country to target first, roughly how much they could sell, or who to partner with — while hiring a dedicated BD analyst is expensive (annual salary ¥300,000–500,000), and commissioning a single report from a consultancy costs ¥150,000–300,000.
Our approach: based on a 233-country global drug screening methodology, your product parameters are entered and the system automatically completes global market tiering, sales forecasting and distributor matching — which BD consultants then interpret into executable going-overseas conclusions. What you receive is a report you can make decisions on directly.
Service plans & pricing
| Plan | Price | Deliverable | Timeline |
|---|---|---|---|
| Starter Overseas Quick-view Report |
¥9,800 one-time |
For 1 selected product: Top 10 target-market ranking + per-country sales forecasts + list of key distributors (PDF, approx. 20–30 pages) | 3–5 working days |
| Popular Overseas In-depth Report |
¥29,800 one-time |
For 1–2 focus countries, a complete BD report: market-access pathway + sales forecasts + reimbursement value & margin + distributor contact list + recommended partnership model (PDF 40–60 pages) | 1–2 weeks |
| Annual subscription Overseas Advisory Subscription |
¥68,000 /year |
12 months of unlimited single-product assessments (each delivered in ≤3 days) + a dedicated advisor group + quarterly going-overseas opportunity briefings | Annual |
Optional add-ons
| Add-on | Price | Description |
|---|---|---|
| Phone debrief session | ¥3,000/session | 15–30 minutes covering why these 3 countries were chosen, where the risks lie and what to do next |
| Focus-country supplement | ¥5,000/country | An in-depth single-country analysis added on top of the quick-view report for any country |
| Data calibration | ¥8,000/session | Introduces authoritative paid data sources to recalibrate key forecasts a second time |
In one line: spend ¥9,800 to try it once — if you are not satisfied, don't buy again. For a small cost, turn "going overseas" from an idea into an executable first step.
Mid-to-large enterprises · Full-process engagement reference (priced in USD)
For pharma companies with a defined overseas pipeline that need full-process execution or dedicated reimbursement support. Reference pricing is tiered by engagement model and target market; the final figure is set by health-economic forecasting and commercial negotiation.
| Model | Market | Fixed fee | Revenue-share | Notes |
|---|---|---|---|---|
| Access-focused | Global average / general | $600,000 | $50,000 + 60% of sales | Reference for reimbursement-oriented full-process execution |
| Full-process engagement | Global average / general | $600,000 | $50,000 + 60% of sales | |
| Access-focused | South Africa | $300,000 | $50,000 + 30% of sales | Flagship case market (Southern Africa hub) |
| Full-process engagement | South Africa | $1,240,000 | $50,000 + 60% of sales | |
| Access-focused | Saudi Arabia | $300,000 | $100,000 + 30% of sales | GCC (Gulf) focus |
| Full-process engagement | Saudi Arabia | $900,000 | $100,000 + 60% of sales | |
| Access-focused | Brazil | $300,000 | $100,000 + 30% of sales | Key Latin American market |
| Full-process engagement | Brazil | $810,000 | $100,000 + 60% of sales | |
| Access-focused | United States | $500,000 | $200,000 + 30% of sales | High-value developed market |
| Full-process engagement | United States | $1,500,000 | $200,000 + 60% of sales |
Basis for reference: the above are market-tiered reference prices (in USD) for standardized overseas-assessment projects at mid-to-large enterprises; final terms are determined by health-economic forecasting and commercial negotiation. Pharma companies retain full product ownership throughout; Qiyang is compensated as a "fixed service fee + sales revenue share".
Free for clients: clients who engage us for full-process execution above receive the corresponding standardized overseas-assessment report free of charge (one of the quick-view / in-depth / subscription tiers).
Why choose Qiyang
| Comparison | In-house BD analyst | Consulting firm | This Qiyang service |
|---|---|---|---|
| Upfront investment | Salary ¥300,000–500,000/yr | ¥150,000–300,000 per report | From ¥9,800 |
| Time to conclusions | 2–4 weeks | 4–8 weeks | 3–5 days |
| Software training needed | Yes | No (but costly) | No (zero training) |
| Small trial order possible | No | No | Yes (try once for ¥9,800) |
| Reuse later | Ongoing labour cost | Repeat payment per pipeline | Unlimited reuse after subscribing |
Enterprise / platform plans are customised on request: software and platform licensing, pharmacoeconomic pricing support, and full-process going-overseas engagement (including revenue-share models) are all quoted to your product and target markets and are not published here. Please contact us for a commercial proposal.
Data basis: WHO/IHME GBD 2022 + World Bank WDI 2023 + OFAC 2025 + public information on national regulatory frameworks. Report conclusions are estimates based on public data, used to prioritise going-overseas initiatives rather than as precise financial forecasts. Prices on this page are valid for 90 days (from September 2026).
Digital Platform
Qiyang's in-house-developed Digital Platform turns assessment into a tool: 233-country funnel screening, a three-tier evidence system, CEA model building and automated AMCP/NICE Value Dossier generation — making it possible to complete global market assessments faster, better and more economically.
Learn about the Digital Platform →PLATFORM FEATURES
AI drug screening engine · Global market screening · CEA model building · Value Dossier generation · Outputs aligned to AMCP/NICE and other review formats.
The Digital Platform is developed in-house by Qiyang. For platform licensing and demo bookings, please contact us for a commercial proposal.
How it works
| Step | What happens | Your part |
|---|---|---|
| 1. Submit | Provide product information (name / dosage form / therapeutic area / target price) | About 10 minutes to fill in a form |
| 2. Assess | Run the global screening methodology + BD consultant interpretation | No action needed |
| 3. Deliver | Receive the PDF report | Read the conclusions |
| 4. Debrief (optional) | Phone debrief of key conclusions and next steps | Set aside 30 minutes |
Start your assessment now
Submit your product information and Qiyang will reply within 1 business day with an assessment recommendation and quote.
Submit your request